retatrutide safety profile Efficacy and of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 Retatrutide Significantly Reduces Visceral Fat

The research has been published in The BMJ

Going from 4mg to 8mg represents a doubling, and the GI adjustment can be rougher than earlier increases

One of the hottest classes of drugs in the world owes part of its origin story to a weird desert lizard with a venomous bite and a prehistoric-looking face

injections of 50 nmol kg 1 GLP-1MK-801 ( n = 6 mice and n = 3 cages), 100 nmol kg 1 GLP-1MK-801 ( n = 6 mice and n = 3 cages) or vehicle (isotonic saline, n = 6 mice and n = 3 cages) for 6 days

While the overall risk appears to be small, I now screen more carefully for patients with risk factors such as pre-existing optic nerve problems, glaucoma, or significant diabetic retinopathy. Recent research also connects liraglutide, the active ingredient in Saxenda and Victoza, to similar concerns

Understanding Semaglutide Semaglutide is an FDA-approved GLP-1 receptor agonist, prescribed for adults dealing with obesity or those who are overweight and have at least one related condition